BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:BIO.B • US0905721082
312.75 USD
+2.05 (+0.66%)
Last: Jan 20, 2026, 08:04 PM
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year BIO.B was profitable.
- BIO.B had a positive operating cash flow in the past year.
- In multiple years BIO.B reported negative net income over the last 5 years.
- BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of BIO.B (-6.97%) is comparable to the rest of the industry.
- BIO.B has a Return On Equity of -10.03%. This is comparable to the rest of the industry: BIO.B outperforms 51.72% of its industry peers.
- With a decent Return On Invested Capital value of 2.26%, BIO.B is doing good in the industry, outperforming 60.34% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- With a decent Operating Margin value of 10.27%, BIO.B is doing good in the industry, outperforming 68.97% of the companies in the same industry.
- BIO.B's Operating Margin has been stable in the last couple of years.
- BIO.B has a better Gross Margin (52.42%) than 62.07% of its industry peers.
- In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO.B is destroying value.
- The number of shares outstanding for BIO.B has been reduced compared to 1 year ago.
- BIO.B has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
- BIO.B has an Altman-Z score of 3.43. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.43, BIO.B is in the better half of the industry, outperforming 67.24% of the companies in the same industry.
- BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
- BIO.B has a better Debt to FCF ratio (3.57) than 75.86% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
- BIO.B has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.43 |
ROIC/WACC0.21
WACC10.73%
2.3 Liquidity
- BIO.B has a Current Ratio of 5.44. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 5.44, BIO.B belongs to the top of the industry, outperforming 84.48% of the companies in the same industry.
- A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
- BIO.B has a Quick ratio of 3.94. This is in the better half of the industry: BIO.B outperforms 67.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO.B have decreased by -1.90% in the last year.
- BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
- Looking at the last year, BIO.B shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
- BIO.B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 30.33, which means the current valuation is very expensive for BIO.B.
- BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 68.97% of the companies in the same industry.
- BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.30, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 30.12 indicates a quite expensive valuation of BIO.B.
- BIO.B's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 65.52% of the companies in the same industry.
- BIO.B's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.57.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.33 | ||
| Fwd PE | 30.12 |
4.2 Price Multiples
- BIO.B's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 77.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.05 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.87
EPS Next 2Y0.36%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
- BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.